PhysIQ, which focuses on patient monitoring and analytics, unveiled its latest offering for CROs and other life sciences research groups and drug developers that provides near real-time patient data.
The Intrepid Partner Program was designed to extend the company’s reach in the industry by signing on CROs, academic research organizations and other tech companies to use physIQ’s portfolio of artificial-intelligence-based digital biomarkers, experience with government regulators and other technologies in clinical operations, the company said in a Nov. 9 press release.
The program is also expected to help diversify clinical trials through the recruitment of patients from underrepresented populations, which has been a growing focus in the clinical trial arena.
“These next generation medical insights will redefine the decentralized clinical trial, significantly expand trial diversity, and enable access to a higher quality of care, particularly for underserved populations,” John Varaklis, physIQ’s chief strategy officer, said in the press release.
In August, physIQ announced it was teaming up with CRO Syneos Health for the phase 3 RESTORE-1 study of InCarda Therapeutics’ inhaled cardiovascular treatment. PhysIQ’s contribution to the study was its wearable sensors and FDA-cleared atrial fibrillation digital biomarker.